Low-grade Glioma Clinical Trials

27 recruitingLast updated: June 18, 2026

There are 27 actively recruiting low-grade glioma clinical trials across 34 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1. Top locations include San Francisco, California, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Low-grade Glioma Trials at a Glance

27 actively recruiting trials for low-grade glioma are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in San Francisco, New York, and Boston. Lead sponsors running low-grade glioma studies include University of California, San Francisco, Day One Biopharmaceuticals, Inc., and Children's Hospital of Philadelphia.

Browse low-grade glioma trials by phase

Treatments under study

About Low-grade Glioma Clinical Trials

Looking for clinical trials for Low-grade Glioma? There are currently 25 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Low-grade Glioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Low-grade Glioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 1

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

High Grade GliomaLow-grade GliomaRecurrent World Health Organization (WHO) Grade II Glioma
University of California, San Francisco50 enrolled17 locationsNCT04485559
Recruiting
Phase 3

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Low-grade GliomaLow Grade AstrocytomaWHO Grade 2 Glioma+3 more
National Cancer Institute (NCI)170 enrolled132 locationsNCT04166409
Recruiting
Phase 2

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco96 enrolled7 locationsNCT07110246
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled82 locationsNCT05538130
Recruiting
Phase 1Phase 2

Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

Pediatric Low-grade Glioma
St. Justine's Hospital50 enrolled8 locationsNCT06666348
Recruiting
Not Applicable

Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas

Low-grade Glioma
University of California, San Francisco97 enrolled1 locationNCT03948490
Recruiting

Low-grade Gliomas in Argentina: Incidence, Survival, and Therapeutic Strategies

Low-grade Glioma
Hospital Italiano de Buenos Aires40 enrolled6 locationsNCT07631338
Recruiting
Phase 1

A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

Low-grade Glioma
Ipsen6 enrolled6 locationsNCT07441707
Recruiting
Early Phase 1

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

GliomaGlioma, MalignantLow-grade Glioma+2 more
Children's Hospital of Philadelphia30 enrolled1 locationNCT05555550
Recruiting
Not Applicable

Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma

Pediatric CancerLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco40 enrolled1 locationNCT07506239
Recruiting
Phase 3

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Low-grade GliomaRapidly Accelerated Fibrosarcoma (RAF) Altered GliomaPediatric Low-grade Glioma
Day One Biopharmaceuticals, Inc.400 enrolled138 locationsNCT05566795
Recruiting
Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

Solid TumorSolid Tumor, AdultNeuroblastoma+12 more
Memorial Sloan Kettering Cancer Center23 enrolled2 locationsNCT06104488
Recruiting
Phase 2

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

Malignant Brain NeoplasmMeningiomaLow-grade Glioma+1 more
Emory University200 enrolled1 locationNCT06132685
Recruiting
Phase 1Phase 2

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

Low-grade GliomaRecurrent Low Grade GliomaProgressive Low-Grade Glioma
St. Jude Children's Research Hospital132 enrolled1 locationNCT04923126
Recruiting

A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors

High Grade GliomaLow-grade Glioma
Maastricht Radiation Oncology50 enrolled1 locationNCT04865315
Recruiting
Phase 2

A Vaccine Trial for Low Grade Gliomas

Low-grade Glioma
James Felker25 enrolled1 locationNCT02358187
Recruiting
Not Applicable

Developing Fast Pediatric Imaging

Pediatric Low-grade Gliomas
Boston Children's Hospital300 enrolled3 locationsNCT03761121
Recruiting
Not Applicable

HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)

Brain NeoplasmsBrain TumorCognitive Dysfunction+9 more
Dartmouth-Hitchcock Medical Center125 enrolled1 locationNCT06930846
Recruiting
Phase 1Phase 2

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

High Grade GliomaLow-grade Glioma
Ann & Robert H Lurie Children's Hospital of Chicago27 enrolled3 locationsNCT06712875
Recruiting
Early Phase 1

Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Low-grade Glioma
Daniel Morgenstern57 enrolled1 locationNCT06381570